Hong Kong – Skadden Advises Everest Medicines In Its HK1,572.50 Million Placing And Subscription Agreement.

Hong Kong – Skadden Advises Everest Medicines In Its HK1,572.50 Million Placing And Subscription Agreement.

Skadden advised Everest Medicines, a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, in its placing of existing shares and top-up subscription of new shares under general mandate, raising HK$1,572.50 million (US$200 million). The transaction was completed on August 1, 2025. Further details about the transaction can be found here. The Skadden team was led b…